What Scott Kanoski has said about GLP-1 receptor agonists

Kanoski says there are no data on GLP-1 microdosing and he wants randomized controlled trials before believing it works.

“I'm old-fashioned, and I like to see the large clinical trials, randomized controlled clinical trials, before I start to believe something's actually working”

Huberman Lab: How Food Choices Shape Memory, Cognition & Cravings | Dr. Scott Kanoski (Oct 12, 2026) · Listen from 6:32

Kanoski says it is unclear whether newer GLP-1 drugs like Ozempic and Wegovy enter the brain, unlike earlier-generation drugs.

“Whether these newer generation GLP-1 drugs like Ozempic, Wegovy, are getting into the brain is less clear”

Huberman Lab: How Food Choices Shape Memory, Cognition & Cravings | Dr. Scott Kanoski (Oct 12, 2026) · Listen from 7:47

Kanoski says he is not concerned about GLP-1-induced micronutrient deficiencies because most users discontinue within two years.

“People don't take, in general, they don't take these GLP-1 drugs for a long period of time. A majority will discontinue treatment within two years of starting”

Huberman Lab: How Food Choices Shape Memory, Cognition & Cravings | Dr. Scott Kanoski (Oct 12, 2026) · Listen from 1:07:40

Kanoski warns that GLP-1 use in lean individuals carries unknown risks because trials in that population have not been done.

“I think there are a lot of potential issues with GLP-1-based drug use in lean individuals that we just don't have any grasp on”

Huberman Lab: How Food Choices Shape Memory, Cognition & Cravings | Dr. Scott Kanoski (Oct 12, 2026) · Listen from 1:08:43